Evidence map›Paper›PMID 36388917›Full record

SynthesisFrontiers in medicine2022

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis.

Wenqiang Qi, Yongheng Zhou, Zhifeng Liu, Jian Wang, Guangda Lv, Minglei Zhong, Wenfu Wang, Rongyang Li, Shouzhen Chen, Benkang Shi and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenqiang QiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Yongheng ZhouDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Zhifeng LiuDepartment of Urology, Taian City Central Hospital, Taian, China.
Jian WangDepartment of Urology, People's Hospital of Laoling, Dezhou, China.
Guangda LvDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Minglei ZhongDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Wenfu WangDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Rongyang LiDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Shouzhen ChenDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Benkang ShiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Yaofeng ZhuDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A novel inflammatory marker called the systemic immune-inflammation index (SII) was applied to predict the prognosis of different cancers. However, the role of SII in prostate cancer (PCa) remains unclear. This systematic review aims to explore the prognostic role of SII in different stage PCa. Methods: We comprehensively searched three public databases: PubMed, EMBASE, and the Cochrane Library. The hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were extracted to evaluate the association between SII and the prognosis and clinicopathological characteristics in different stage PCa patients. Results: Ten studies and 7,986 patients were enrolled in our meta-analysis, 1,442 patients were diagnosed with metastatic-castration resistant prostate cancer (mCRPC), and 6544 patients were diagnosed with non-metastatic prostate cancer (nmPCa). According to the pooled results, we found that a high SII was associated with worse overall survival (OS) in mCRPC patients (HR = 1.94, 95% CI: 1.26-3.01, Conclusion: High SII was associated with bad OS in mCRPC patients, and associated with bad BFS and some adverse pathological features in nmPCa patients. We think SII can be a prognostic predictor for PCa patients. The application of SII will advance the diagnosis and treatment of different stage prostate cancer.

Indexed as

meta-analysismetastatic castration-resistant prostate cancer (mCRPC)non-metastatic prostate cancerprognosissystematic reviewsystemic immune-inflammation index

Identifiers

PMID36388917
PMCPMC9659961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.